CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
J. Wang,Z. Wang,L. Wu,B. Li,Y. Cheng,X. Li,X. Wang,L. Han,X. Wu,Y. Fan,Y. Yu,D. Lv,J. Shi,J. Huang, S. Zhou,B. Han,G. Sun,Q. Guo,Y. Ji,X. Zhu,S. Hu,W. Zhang,Q. Wang,Y. Jia,Z. Wang,Y. Song,J. Wu,M. Shi,X. Li,Z. Han, Y. Liu,Z. Yu,A. Liu,X. Wang,C. Zhou,D. Zhong,L. Miao,Z. Zhang,H. Zhao,J. Yang,D. Wang,Y. Wang,Q. Li,X. Zhang,M. Ji,Z. Yang,J. Cui,B. Gao,B. Wang,H. Liu,L. Nie,M. He,S. Jin,W. Gu,Y. Shu,T. Zhou,J. Feng,X. Yang,C. Huang,B. Zhu,Y. Yao,Y. Wang,X. Kang, S. Yao,P. Keegan JOURNAL OF THORACIC ONCOLOGY（2021）
关键词
anti-PD-1, 1st line treatment for NSCLC, Toripalimab
AI 理解论文
溯源树
样例
